Analysis of the time course and prognostic factors determining XXXX due to infused @entity1487 .

@entity1 @entity137 @entity3136 @entity5 @entity294 @entity648 @entity1820 @entity31339 @entity493 @entity1487
This study used a prospectively managed clinical database in order to identify 1470 @entity1 with @entity1820 receiving protracted venous infusion (PVI) @entity1487 (5FU). It aimed to determine the time course of @entity137 due to PVI 5FU and to analyse factors predicting @entity137 . The initial development of @entity3136 occurred more rapidly than @entity294 or @entity31339 ( @entity31339 ). The percentage of @entity1 with National @entity5 Institute Common @entity137 Criteria (CTC) grade 2 or worse @entity31339 peaked at 9% between weeks 8 and 17, whereas this peak occurred earlier for @entity3136 and @entity294 . The development of CTC grade 1 @entity137 in the first 28 days after commencement of chemotherapy was classified as early grade 1 @entity137 . Multivariate Cox regression analysis showed that female sex, better performance status, elevated @entity648 , early grade 1 @entity31339 and early grade 1 @entity294 were independent prognostic factors for the development of CTC grade 2 or worse @entity31339 (P<0.01). Female sex, increased age, elevated @entity493 transaminase and urea and early grade 1 @entity31339 were significant independent prognostic factors for the development of CTC grade 2 or worse @entity3136 (P<0.01). Early CTC grade 1 @entity294 predicted CTC grade 2 or worse @entity294 (P<0.01). Older, female @entity1 with good performance status and impaired liver and renal function who develop early grade 1 @entity31339 alone or in combination with @entity294 are at highest risk of subsequently developing grade 2 or worse @entity31339 or @entity3136 during treatment with PVI 5FU. Reduction of infused 5FU dose should be considered for these @entity1 . Such an approach could both reduce severe @entity137 owing to chemotherapy and minimise treatment delays, and should be evaluated prospectively.
